X4 Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

X4 Pharmaceuticals şirketinin kazançlarının yıllık 8.9% oranında düşmesi, yıllık gelirinin ise yıllık 64.3% oranında artması bekleniyor. EPS'nin yıllık 14.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

-8.9%

Kazanç büyüme oranı

14.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	64.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:XFOR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	54	-122	-97	N/A	6
12/31/2025	15	-140	N/A	N/A	7
12/31/2024	2	-47	N/A	N/A	7
9/30/2024	1	-17	-133	-126	N/A
6/30/2024	1	18	-120	-112	N/A
3/31/2024	N/A	-129	-104	-104	N/A
12/31/2023	N/A	-101	-97	-97	N/A
9/30/2023	N/A	-111	-88	-88	N/A
6/30/2023	N/A	-131	-86	-86	N/A
3/31/2023	N/A	-96	-83	-83	N/A
12/31/2022	N/A	-96	-77	-77	N/A
9/30/2022	N/A	-103	-77	-77	N/A
6/30/2022	N/A	-102	-72	-72	N/A
3/31/2022	N/A	-100	-73	-73	N/A
12/31/2021	N/A	-103	-72	-71	N/A
9/30/2021	N/A	-85	-70	-69	N/A
6/30/2021	N/A	-82	-71	-69	N/A
3/31/2021	N/A	-78	-63	-62	N/A
12/31/2020	3	-62	-60	-59	N/A
9/30/2020	3	-55	-52	-51	N/A
6/30/2020	3	-55	-50	-49	N/A
3/31/2020	3	-53	-53	-52	N/A
12/31/2019	N/A	-53	-48	-48	N/A
9/30/2019	N/A	-55	-46	-46	N/A
6/30/2019	N/A	-46	-40	-39	N/A
3/31/2019	N/A	-40	-31	-31	N/A
12/31/2018	N/A	-36	-25	-25	N/A
9/30/2018	N/A	-31	-23	-23	N/A
12/31/2017	N/A	-25	N/A	-21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: XFOR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: XFOR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: XFOR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: XFOR şirketinin gelirinin (yıllık 64.3% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: XFOR şirketinin gelirinin (yıllık 64.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: XFOR 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

X4 Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 8.9% to US$3.68

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$3.55

Price target increased by 13% to US$3.65

Price target decreased by 8.9% to US$3.20

Price target increased by 7.5% to US$3.76

Recent updates

New major risk - Financial position

Price target decreased by 8.9% to US$3.68

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

CEO, President & Director notifies of intention to sell stock

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Founder notifies of intention to sell stock